Stay updated on COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Sign up to get notified when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.

Latest updates to the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedIn the log, Revision: v3.5.0 was added and Revision: v3.4.3 was crossed out.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision: v3.4.3 was added, replacing v3.4.2.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check46 days agoChange DetectedRevision: v3.4.2 was added as the latest version in the study's history, replacing the earlier v3.4.1. The notice about government funding and operating status was removed from the page.SummaryDifference0.3%

- Check54 days agoChange DetectedThe page shows two minor administrative updates: a site-wide notice regarding government funding and a new revision tag (v3.4.1) that supersedes v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check61 days agoChange DetectedThe history page adds a glossary display option and color-coded highlights for additions and deletions, and updates the revision label from v3.3.4 to v3.4.0.SummaryDifference0.3%

- Check75 days agoChange DetectedRevision history updated: added Revision v3.3.4 and removed Revision v3.3.3.SummaryDifference0.0%

Stay in the know with updates to COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Enter your email address, and we'll notify you when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.